Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering

Mr. Vat-Ho's appointment brings more than 20 years of oncology, biopharma and capital-markets experience. His senior roles included transactions with more than $25 billion in aggregate value; the article provides no further details about the appointment's expected financial or market impact.